DR. FUMIHIKO URANO Regenerative Gene Therapy- Dr.
Post# of 30028
(Total Views: 613)
Posted On: 10/01/2020 11:15:55 AM
.jpg)
DR. FUMIHIKO URANO
Regenerative Gene Therapy- Dr. Fumihiko Urano, MD, PhD
OCTOBER 1, 2020/BY THE SNOW FOUNDATION
My current focus is to develop gene therapy for Wolfram syndrome. Our ultimate goal is to provide a cure using regenerative gene therapy. We have been trying to improve diabetes, visual acuity, and brain functions using viral vectors of a healthy Wolfram gene and a regenerative factor called MANF in mouse models. We are getting encouraging preliminary results and have published two articles recently. We are currently testing two ways to deliver genes through intravitreal (for optic nerve) and intraventricular (for brain) injections.
http://thesnowfoundation.org/regenerative-gen...no-md-phd/
TREATMENT
Amarantus Bioscience: MANF
AUGUST 28, 2020/BY THE SNOW FOUNDATION
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics.
http://thesnowfoundation.org/amarantus-bioscience-manf/
Regenerative Gene Therapy- Dr. Fumihiko Urano, MD, PhD
OCTOBER 1, 2020/BY THE SNOW FOUNDATION
My current focus is to develop gene therapy for Wolfram syndrome. Our ultimate goal is to provide a cure using regenerative gene therapy. We have been trying to improve diabetes, visual acuity, and brain functions using viral vectors of a healthy Wolfram gene and a regenerative factor called MANF in mouse models. We are getting encouraging preliminary results and have published two articles recently. We are currently testing two ways to deliver genes through intravitreal (for optic nerve) and intraventricular (for brain) injections.
http://thesnowfoundation.org/regenerative-gen...no-md-phd/
TREATMENT
Amarantus Bioscience: MANF
AUGUST 28, 2020/BY THE SNOW FOUNDATION
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (cell death) in response to injury or disease, via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics.
http://thesnowfoundation.org/amarantus-bioscience-manf/
(3)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼